Friday, November 13, 2026

Dollar Index Crashes 10.8% as Forex Markets Enter Volatility Phase

The US Dollar Index dropped 10.8% in early 2026 to its lowest point since 2022, triggering widespread currency realignment. GBP/USD faces pressure toward $1.30 despite 7% gains in 2025, while safe-haven flows boost the Swiss Franc amid systemic instability concerns.

Dollar Index Crashes 10.8% as Forex Markets Enter Volatility Phase
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The US Dollar Index tumbled 10.8% in early 2026, hitting levels not seen since 2022 and forcing traders to reassess positions across major currency pairs. The decline marks the sharpest dollar retreat in recent years, creating opportunities in forex and commodity-linked currencies.

GBP/USD dropped 0.5% to $1.3086 despite the pound's 7% rally through 2025. Analysts forecast further downside below $1.30 ahead of the UK budget on November 26 and the Federal Reserve chair transition in June 2026. Simon Phillips, Managing Director at No1 Currency, cited mounting pressure on sterling from fiscal uncertainty. Jordan Rochester at Mizuho Bank sees $1.30 as the next technical level.

The pound fell 0.4% against the euro to €1.13, its weakest since April 2023. UK 30-year gilt yields climbed 4 basis points to 5.21%, the highest since 1998. Neil Wilson at Saxo Markets warned of fiscal instability risk as Chancellor Rachel Reeves prepares tax increases to address public finance gaps.

Safe-haven currencies gained traction on dollar weakness. The Swiss Franc attracted flows as traders positioned for extended volatility in global markets. Systemic instability concerns, amplified by the Fed leadership change and geopolitical tensions, drove demand for non-dollar reserves.

Emerging market currencies faced severe pressure. The Turkish Lira collapsed following carry trade unwinding, exposing vulnerability in high-yield positions. The dollar decline offered limited relief to EM currencies as risk-off sentiment dominated.

Commodity currencies showed mixed performance. Gold pushed above $4,100 per ounce, benefiting from dollar weakness and inflation hedging demand. WTI crude rose 1.5% to $61 per barrel, while Brent topped $65. Resource-linked currencies like the Australian and Canadian dollars gained modest ground.

Trading opportunities center on dollar crosses and volatility plays. EUR/USD and USD/JPY pairs show heightened two-way action. Options markets price elevated implied volatility through mid-2026, reflecting uncertainty around Fed policy direction under new leadership.

The FTSE 100 hit a record 9,911 points, up 0.1%, while European equities rallied on weaker dollar tailwinds. The Stoxx 600 climbed 0.6% to 583.4 points. Currency hedging costs for UK exporters declined as sterling weakened against the euro.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· March 7, 2026
    Ray Dalio says America is facing a ‘debt death spiral’ — but you can protect your portfolio with these 3 assets
  3. [3]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  4. [4]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com